CA2409652A1 - Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents - Google Patents
Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents Download PDFInfo
- Publication number
- CA2409652A1 CA2409652A1 CA002409652A CA2409652A CA2409652A1 CA 2409652 A1 CA2409652 A1 CA 2409652A1 CA 002409652 A CA002409652 A CA 002409652A CA 2409652 A CA2409652 A CA 2409652A CA 2409652 A1 CA2409652 A1 CA 2409652A1
- Authority
- CA
- Canada
- Prior art keywords
- her2
- aromatase inhibitor
- antibody against
- human
- exemestane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor e.g. exemestane, fadrozole, letrozole and anastrozole and an antibody against HER2 e.g. trastuzumab, in amounts effective to produce a superadditive or synergistic therapeutic effect.
Description
aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents The present invention concerns the treatment of hormone dependent disorders characterized by the overexpression of HER2. More specifically, the invention concerns the treatment of a human being susceptible to or diagnosed with a disorder characterized by the overexpression of HER2 with a combination of an anti-HER2 antibody and an aromatase inhibitor.
Proto-oncogens that encode growth factors and growth factors receptors have been identified to play important roles in the pathogenesis of various malignancies, including breast cancer. In particular numerous studies have demonstrated the prognostic relevance of p185(HER2), which is overexpressed in 10% to 400 of human breast tumors. Moreover a recombinant humanized anti-HER2 monoclonal antibody (a humanized version of the murine anti-HER-2 antibody 4D5, referred to as Herceptin~) has been found clinically active in patients with HER2-overexpressing breast cancer (J. Clin. Oncol. 14:737-744, 1996). Also the utility of aromatase inhibitors is well acknowledged in anticancer therapy. However, it is also well known in the art that administration to a patient of therapeutically effective amounts of aromatase inhibitors can. cause considerable side effects. The major toxicities are for instance lethargy, hot flashes, rash, transient leukopenia, dizzines, nausea, constipation and vomiting.
On the other hand, also administration to a patient of therapeutically effective amounts of an antibody against HER2 can similarly cause considerable side effects, e.g.
hypersensitivity, alterations of renal function, myocardial lesions and cardiotoxicity in general.
SUBSTITUTE SHEET (RULE 26) The inventors of the present invention have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of an antibody against HER2, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either a sole aromatase inhibitor or a sole antibody against HER2.
Similarly they have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically sub-effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an antibody against HER2, can produce substantially the same therapeutic effect, which is obtainable by single administration of a therapeutically effective amount of either an aromatase inhibitor or an antibody against HER2.
The most important, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administrations of either therapeutically effective amounts of an aromatase inhibitor or therapeutically effective amounts of an anti-HER2 antibody.
In view of the above, the effectiveness of an aromatase inhibitor and an antibody against HER2 is significantly increased without a parallel increased toxicity. In other words, the combined. therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the antibody against HER2 and thus yields more effective and less toxic treatment for h.ormone-dependent disorders.
Accordingly, the present invention provides a new and valuable tool in the therapy of hormone dependent SUBSTITUTE SHEET (RULE 26) disorders characterized by the overexpression of HER2. The advantages provided by the present invention can be appreciated by their preferred features, described herebelow.
Examples of such disorders are cancers, e.g. breast, cervical, ovarian and endometrial cancers, and endometriosis. However such disorder is preferably breast cancer in a human being, in particular a female, Accordingly, the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an antibody against HER2, having a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
The present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2, the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
Examples of aromatase inhibitors according to the invention are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17 dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
Preferred examples of aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane.
SUBSTITUTE SHEET (RULE 26) The aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat-Res.: 94, 231-254, 1998 and WO 99/30708.
Unless otherwise indicated, the terms "HER2" and ErbB2"
when used herein refer to the human protein and are used interchangeably.
An antibody against HER2, according to the invention, can be either and "intact" antibody or a fragment thereof.
The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e. g.
bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. "Antibody fragments"
l5 comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single chain antbody molecules; and multispecific antibodies formed from antibody fragments.
A preferred example of an antibody against HER2 is trastuzumab.
The recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin°) is described in various scientific publications, for example Cancer Res., 1998, 58: 2825-2831.
The present invention also provides a product comprising an aromatase inhibitor and an antibody against HER2, as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
SUBSTITUTE SHEET (RULE 26) In a further aspect, the present invention provides a kit comprising, in a suitable container means, a pharmaceutical composition containing an aromatase inhibitor, as an active agent, and an antibody against 5 HER2, as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-dependent disorder characterized by the overexpression of HER2.
A further aspect of the present invention is to provide a method of treating a human being, particularly a female, suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic therapeutic effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic antitumor effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an antibody against HER2 in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an antibody SUBSTITUTE SHEET (RULE 26) against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
By the term "a superadditive or synergistic antitumor effect" as used herein is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an antibody against a HER2, to a human being, particularly a human female.
Said preparation having therefore a potentiated antitumor (superadditive) activity with respect to products containing either an aromatase inhibitor or an antibody against HER2.
By the term "administered" or "administering" as used herein is meant any acceptable manner of~administering a drug to a patient which is medically acceptable including parenteral and oral administration.
By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.
Oral administration includes administering the costituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.
The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the antibody against the growth factor receptor being utilized, the particular cancer being treated and the particular patient SUBSTITUTE SHEET (RULE 26) being treated.
The dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.
In the combined method of treatment according to the subject invention, the aromatase inhibitor may be administered simultaneously with the antibody against HER2 or the compounds may be administered sequentially, in either order.
An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 times a day. Exemestane, for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg.
Fadrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
Letrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
Formestane, for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
Anastrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
SUBSTITUTE SHEET (RULE 26) In the method of the subject invention, for example for the administration of the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, the course of therapy generally employed is from about 1 to about 1000 mg/m2 of body surface area. More preferably, the course therapy employed is from about 50 to about 500 mg/m2 of body surface area.
The therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of HER2. Typical examples of such disorders are endometriosis and tumors, like ovarian, cervical and endometrial cancers in a human female or breast cancer in a human being, in particular a female.
More in particular, the combined use of an aromatase inhibitor, according to the invention, preferably exemestane, and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the HER2 protein, for example, for patient with breast cancer, in particular with metastatic breast cancer, over-expressing the HER2 protein.
Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.
A pharmaceutically composition containing an aromatase inhibitor and/or an antibody against HER2 can be prepared according to well known techniques to those skilled in the art. For instance a pharmaceutical composition containing exemestane can be prepared according to US 4,808,616.
SUBSTITUTE SHEET (RULE 26)
Proto-oncogens that encode growth factors and growth factors receptors have been identified to play important roles in the pathogenesis of various malignancies, including breast cancer. In particular numerous studies have demonstrated the prognostic relevance of p185(HER2), which is overexpressed in 10% to 400 of human breast tumors. Moreover a recombinant humanized anti-HER2 monoclonal antibody (a humanized version of the murine anti-HER-2 antibody 4D5, referred to as Herceptin~) has been found clinically active in patients with HER2-overexpressing breast cancer (J. Clin. Oncol. 14:737-744, 1996). Also the utility of aromatase inhibitors is well acknowledged in anticancer therapy. However, it is also well known in the art that administration to a patient of therapeutically effective amounts of aromatase inhibitors can. cause considerable side effects. The major toxicities are for instance lethargy, hot flashes, rash, transient leukopenia, dizzines, nausea, constipation and vomiting.
On the other hand, also administration to a patient of therapeutically effective amounts of an antibody against HER2 can similarly cause considerable side effects, e.g.
hypersensitivity, alterations of renal function, myocardial lesions and cardiotoxicity in general.
SUBSTITUTE SHEET (RULE 26) The inventors of the present invention have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of an antibody against HER2, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either a sole aromatase inhibitor or a sole antibody against HER2.
Similarly they have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically sub-effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an antibody against HER2, can produce substantially the same therapeutic effect, which is obtainable by single administration of a therapeutically effective amount of either an aromatase inhibitor or an antibody against HER2.
The most important, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administrations of either therapeutically effective amounts of an aromatase inhibitor or therapeutically effective amounts of an anti-HER2 antibody.
In view of the above, the effectiveness of an aromatase inhibitor and an antibody against HER2 is significantly increased without a parallel increased toxicity. In other words, the combined. therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the antibody against HER2 and thus yields more effective and less toxic treatment for h.ormone-dependent disorders.
Accordingly, the present invention provides a new and valuable tool in the therapy of hormone dependent SUBSTITUTE SHEET (RULE 26) disorders characterized by the overexpression of HER2. The advantages provided by the present invention can be appreciated by their preferred features, described herebelow.
Examples of such disorders are cancers, e.g. breast, cervical, ovarian and endometrial cancers, and endometriosis. However such disorder is preferably breast cancer in a human being, in particular a female, Accordingly, the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an antibody against HER2, having a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
The present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2, the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
Examples of aromatase inhibitors according to the invention are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17 dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
Preferred examples of aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane.
SUBSTITUTE SHEET (RULE 26) The aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat-Res.: 94, 231-254, 1998 and WO 99/30708.
Unless otherwise indicated, the terms "HER2" and ErbB2"
when used herein refer to the human protein and are used interchangeably.
An antibody against HER2, according to the invention, can be either and "intact" antibody or a fragment thereof.
The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e. g.
bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. "Antibody fragments"
l5 comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single chain antbody molecules; and multispecific antibodies formed from antibody fragments.
A preferred example of an antibody against HER2 is trastuzumab.
The recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin°) is described in various scientific publications, for example Cancer Res., 1998, 58: 2825-2831.
The present invention also provides a product comprising an aromatase inhibitor and an antibody against HER2, as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
SUBSTITUTE SHEET (RULE 26) In a further aspect, the present invention provides a kit comprising, in a suitable container means, a pharmaceutical composition containing an aromatase inhibitor, as an active agent, and an antibody against 5 HER2, as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-dependent disorder characterized by the overexpression of HER2.
A further aspect of the present invention is to provide a method of treating a human being, particularly a female, suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic therapeutic effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic antitumor effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an antibody against HER2 in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an antibody SUBSTITUTE SHEET (RULE 26) against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
By the term "a superadditive or synergistic antitumor effect" as used herein is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an antibody against a HER2, to a human being, particularly a human female.
Said preparation having therefore a potentiated antitumor (superadditive) activity with respect to products containing either an aromatase inhibitor or an antibody against HER2.
By the term "administered" or "administering" as used herein is meant any acceptable manner of~administering a drug to a patient which is medically acceptable including parenteral and oral administration.
By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.
Oral administration includes administering the costituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.
The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the antibody against the growth factor receptor being utilized, the particular cancer being treated and the particular patient SUBSTITUTE SHEET (RULE 26) being treated.
The dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.
In the combined method of treatment according to the subject invention, the aromatase inhibitor may be administered simultaneously with the antibody against HER2 or the compounds may be administered sequentially, in either order.
An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 times a day. Exemestane, for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg.
Fadrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
Letrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
Formestane, for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
Anastrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
SUBSTITUTE SHEET (RULE 26) In the method of the subject invention, for example for the administration of the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, the course of therapy generally employed is from about 1 to about 1000 mg/m2 of body surface area. More preferably, the course therapy employed is from about 50 to about 500 mg/m2 of body surface area.
The therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of HER2. Typical examples of such disorders are endometriosis and tumors, like ovarian, cervical and endometrial cancers in a human female or breast cancer in a human being, in particular a female.
More in particular, the combined use of an aromatase inhibitor, according to the invention, preferably exemestane, and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the HER2 protein, for example, for patient with breast cancer, in particular with metastatic breast cancer, over-expressing the HER2 protein.
Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.
A pharmaceutically composition containing an aromatase inhibitor and/or an antibody against HER2 can be prepared according to well known techniques to those skilled in the art. For instance a pharmaceutical composition containing exemestane can be prepared according to US 4,808,616.
SUBSTITUTE SHEET (RULE 26)
Claims (16)
1. Use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2, the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
2. Use, according to claim 1, wherein the disorder' is breast, cervical, ovarian and endometrial cancers, and endometriosis.
3. Use, according to claim 2, wherein the disorder is breast cancer.
4. Use, according to claim 1, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17-dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
5. Use, according to claim 1, wherein the aromatase inhibitor is exemestane.
6. Use, according to claim 1, wherein the antibody against HER2 is trastuzumab.
7. Use, according to claim 3, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab.
8. A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic therapeutic effect.
9. A method for lowering the side effects caused by antitumor therapy with an aromatase inhibitor in a human being suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic antitumor effect.
10. A method for lowering the side effects caused by antitumor therapy with an antibody against HER2 in a human being suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an antibody against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
11. A method according to claim 8, wherein the disorder is breast, cervical, ovarian and endometrial cancers, and endometriosis.
12. A method according to claim 8, wherein the disorder is breast cancer.
13. A method according to claim 8, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17-dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
14. A method according to claim 8, wherein the aromatase inhibitor is exemestane.
15. A method according to claim 8, wherein the antibody against HER2 is trastuzumab.
16. A method according to claim 8, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| US09/571,355 | 2000-05-15 | ||
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2409652A1 true CA2409652A1 (en) | 2001-11-22 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002409652A Abandoned CA2409652A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (en) |
| JP (1) | JP2003533490A (en) |
| KR (1) | KR20030014223A (en) |
| CN (1) | CN1429118A (en) |
| AU (1) | AU784617B2 (en) |
| BR (1) | BR0110732A (en) |
| CA (1) | CA2409652A1 (en) |
| CZ (1) | CZ20023748A3 (en) |
| EA (1) | EA005931B1 (en) |
| EE (1) | EE200200622A (en) |
| HK (1) | HK1054200A1 (en) |
| HU (1) | HUP0301877A2 (en) |
| IL (1) | IL152389A0 (en) |
| MX (1) | MXPA02011194A (en) |
| NO (1) | NO20025302L (en) |
| NZ (1) | NZ523004A (en) |
| PL (1) | PL360153A1 (en) |
| SK (1) | SK16022002A3 (en) |
| WO (1) | WO2001087334A1 (en) |
| ZA (1) | ZA200209815B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| ES2331646T3 (en) | 2000-05-19 | 2010-01-12 | Genentech, Inc. | TEST FOR THE DETECTION OF GENES TO IMPROVE THE PROBABILITY OF AN EFFECTIVE ANSWER TO A THERAPY AGAINST CANCER BASED ON ERBB ANTAGONISTS. |
| DK1377298T3 (en) * | 2001-01-26 | 2007-01-02 | Pfizer Italia Srl | Exemestane for the treatment of hormone-dependent disorders |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
| CA2491427A1 (en) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
| FR2844455B1 (en) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES |
| NZ552091A (en) * | 2004-07-16 | 2009-09-25 | Pfizer Prod Inc | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| PL1846030T3 (en) | 2005-01-21 | 2019-05-31 | Genentech Inc | Fixed dosing of her antibodies |
| UA95902C2 (en) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Extending time to disease progression or survival in cancer patients |
| CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| MA33198B1 (en) | 2009-03-20 | 2012-04-02 | Genentech Inc | ANTI-HER DI-SPECIFIC ANTIBODIES |
| JP5705836B2 (en) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Modulators for HER2 signaling in gastric cancer patients expressing HER2 |
| MX2012008958A (en) | 2010-02-18 | 2012-08-23 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer. |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102068429B (en) * | 2010-12-28 | 2011-12-14 | 西南大学 | Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof |
| MX2014001766A (en) | 2011-08-17 | 2014-05-01 | Genentech Inc | Neuregulin antibodies and uses thereof. |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| CN104220457A (en) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | Diagnosis and treatments relating to her3 inhibitors |
| WO2014015137A2 (en) * | 2012-07-18 | 2014-01-23 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| RU2692773C2 (en) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Identification of patients in need of combined therapy with pd-l1 inhibitor |
| SG11201703279XA (en) | 2014-10-22 | 2017-05-30 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| JP2018534291A (en) | 2015-10-22 | 2018-11-22 | ハバフ セラピューティクス ピーティーワイ エルティーディー | Method for reducing mammography breast density and / or risk of breast cancer |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (en) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | Anti-human ErbB2 bispecific antibody, preparation method and application thereof |
| US11524014B2 (en) | 2019-06-03 | 2022-12-13 | Havah Therapeutics Pty Ltd. | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 PL PL36015301A patent/PL360153A1/en not_active Application Discontinuation
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en active IP Right Grant
- 2001-04-19 CN CN01809581A patent/CN1429118A/en active Pending
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/en not_active IP Right Cessation
- 2001-04-19 EE EEP200200622A patent/EE200200622A/en unknown
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/en not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/en not_active Application Discontinuation
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/en unknown
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/en unknown
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/en not_active Withdrawn
- 2001-04-19 IL IL15238901A patent/IL152389A0/en unknown
- 2001-04-19 EA EA200201213A patent/EA005931B1/en not_active IP Right Cessation
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/en not_active Application Discontinuation
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302L/en not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
-
2003
- 2003-09-11 HK HK03106504.3A patent/HK1054200A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20023748A3 (en) | 2003-04-16 |
| WO2001087334A1 (en) | 2001-11-22 |
| HK1054200A1 (en) | 2003-11-21 |
| IL152389A0 (en) | 2003-05-29 |
| PL360153A1 (en) | 2004-09-06 |
| CN1429118A (en) | 2003-07-09 |
| MXPA02011194A (en) | 2003-03-10 |
| JP2003533490A (en) | 2003-11-11 |
| NO20025302D0 (en) | 2002-11-05 |
| EE200200622A (en) | 2004-06-15 |
| EP1282440A1 (en) | 2003-02-12 |
| KR20030014223A (en) | 2003-02-15 |
| EA005931B1 (en) | 2005-08-25 |
| AU784617B2 (en) | 2006-05-18 |
| NO20025302L (en) | 2002-11-05 |
| SK16022002A3 (en) | 2003-04-01 |
| AU5630901A (en) | 2001-11-26 |
| BR0110732A (en) | 2003-02-04 |
| HUP0301877A2 (en) | 2003-09-29 |
| ZA200209815B (en) | 2003-12-03 |
| NZ523004A (en) | 2004-09-24 |
| EA200201213A1 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU784617B2 (en) | Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents | |
| US20050032759A1 (en) | Antitumor combined therapy | |
| AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
| JP5220315B2 (en) | Anti-EpCAM immunoglobulin | |
| JP2023085422A (en) | ErbB-2/ErbB-3 BISPECIFIC ANTIBODY AND ENDOCRINE THERAPY COMBINATION FOR BREAST CANCER | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| Perry et al. | Trastuzumab | |
| WO2023172906A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| WO2023230605A1 (en) | A method of treating solid tumor | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |